A detailed history of Tower Research Capital LLC (Trc) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,132 shares of TGTX stock, worth $92,519. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,132
Previous 42,939 92.71%
Holding current value
$92,519
Previous $763,000 90.43%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.21 - $25.28 $685,078 - $1.01 Million
-39,807 Reduced 92.71%
3,132 $73,000
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $548,331 - $789,975
41,166 Added 2321.83%
42,939 $763,000
Q1 2024

May 15, 2024

SELL
$13.02 - $21.3 $81,544 - $133,401
-6,263 Reduced 77.94%
1,773 $26,000
Q4 2023

Feb 13, 2024

BUY
$6.68 - $18.81 $15,297 - $43,074
2,290 Added 39.85%
8,036 $137,000
Q3 2023

Nov 14, 2023

SELL
$8.36 - $26.5 $93,514 - $296,429
-11,186 Reduced 66.06%
5,746 $48,000
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $136,177 - $307,895
8,797 Added 108.14%
16,932 $420,000
Q1 2023

May 09, 2023

SELL
$10.23 - $19.34 $340,802 - $644,292
-33,314 Reduced 80.37%
8,135 $123,000
Q4 2022

Feb 10, 2023

SELL
$5.01 - $11.83 $65,575 - $154,842
-13,089 Reduced 24.0%
41,449 $490,000
Q3 2022

Nov 10, 2022

BUY
$4.57 - $8.4 $153,853 - $282,794
33,666 Added 161.3%
54,538 $323,000
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $22,847 - $65,121
6,109 Added 41.38%
20,872 $89,000
Q1 2022

May 12, 2022

BUY
$7.81 - $20.45 $26,850 - $70,307
3,438 Added 30.36%
14,763 $140,000
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $57,304 - $133,872
3,770 Added 49.9%
11,325 $215,000
Q3 2021

Nov 15, 2021

BUY
$21.78 - $40.45 $109,183 - $202,775
5,013 Added 197.21%
7,555 $252,000
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $283,205 - $426,637
-8,714 Reduced 77.42%
2,542 $99,000
Q1 2021

May 17, 2021

BUY
$41.61 - $54.3 $171,641 - $223,987
4,125 Added 57.85%
11,256 $543,000
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $107,700 - $233,983
4,262 Added 148.55%
7,131 $371,000
Q3 2020

Nov 16, 2020

SELL
$18.49 - $27.24 $292,752 - $431,290
-15,833 Reduced 84.66%
2,869 $77,000
Q2 2020

Aug 13, 2020

BUY
$8.9 - $21.84 $166,447 - $408,451
18,702 New
18,702 $365,000
Q1 2020

May 15, 2020

SELL
$7.14 - $15.99 $714 - $1,599
-100 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$5.1 - $11.2 $8,858 - $19,454
-1,737 Reduced 94.56%
100 $1,000
Q3 2019

Nov 05, 2019

SELL
$5.38 - $8.99 $50,776 - $84,847
-9,438 Reduced 83.71%
1,837 $11,000
Q2 2019

Aug 13, 2019

BUY
$6.27 - $8.65 $70,694 - $97,528
11,275 New
11,275 $98,000
Q1 2019

May 14, 2019

SELL
$4.02 - $8.04 $5,045 - $10,090
-1,255 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$3.44 - $5.76 $24,812 - $41,546
-7,213 Reduced 85.18%
1,255 $5,000
Q3 2018

Nov 13, 2018

BUY
$5.15 - $14.0 $15,661 - $42,574
3,041 Added 56.03%
8,468 $48,000
Q2 2018

Aug 15, 2018

BUY
$12.5 - $15.0 $35,000 - $42,000
2,800 Added 106.59%
5,427 $71,000
Q1 2018

May 15, 2018

BUY
$8.7 - $16.8 $20,871 - $40,303
2,399 Added 1052.19%
2,627 $37,000
Q4 2017

Feb 09, 2018

BUY
$7.35 - $12.3 $1,675 - $2,804
228
228 $2,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.